<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated a new concept in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy, coiled-coil mediated induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in Raji B cells, for treatment of human B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in a preclinical animal model </plain></SENT>
<SENT sid="1" pm="."><plain>The system is composed of a pair of complementary coiled-coil <z:chebi fb="7" ids="16670">peptides</z:chebi>, CCE and CCK, forming antiparallel heterodimers; Fab' fragment of the 1F5 anti-CD20 antibody; and N-(2-hydroxypropyl)<z:chebi fb="0" ids="51759">methacrylamide</z:chebi> (<z:chebi fb="0" ids="53440">HPMA</z:chebi>) <z:chebi fb="5" ids="53310">copolymer</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>One <z:chebi fb="7" ids="16670">peptide</z:chebi> is conjugated to the Fab' fragment (Fab'-CCE), the other is conjugated in multiple grafts to polyHPMA (CCK-P; P is the <z:chebi fb="0" ids="53440">HPMA</z:chebi> <z:chebi fb="5" ids="53310">copolymer</z:chebi> backbone) </plain></SENT>
<SENT sid="3" pm="."><plain>Intravenous administration of Fab'-CCE conjugate, followed by the administration of CCK-P produced long-term survivors in <z:mp ids='MP_0002536'>SCID</z:mp> (C.B.-17) mice bearing human B-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> xenografts </plain></SENT>
<SENT sid="4" pm="."><plain>The rationale of the design is the absence of low molecular weight drugs and the fact that crosslinking of CD20 at B-cell surface results in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>This approach creates a new paradigm for manipulating molecular recognition principles in the design of improved <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
</text></document>